Search
Peripheral Vascular Disease Clinical Trials
A listing of 3 Peripheral Vascular Disease clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
There are currently 3 active clinical trials seeking participants for Peripheral Vascular Disease research studies. The states with the highest number of trials for Peripheral Vascular Disease participants are Florida, California, Texas and New York.
Featured Trial
Peripheral vascular disease Clinical Study
Recruiting
A clinical study for people that suffer with Peripheral vascular disease
Conditions:
Peripheral vascular disease
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
Recruiting
The purpose of this study is to test the effects of leg exercise assistive paddling (LEAP) therapy during prolonged sitting (PS) on vascular and functional performance in those with peripheral artery disease (PAD) and age-matched controls. LEAP therapy is a novel application of passive limb movement to enhance blood flow through the legs without muscular contractions. Specifically, LEAP therapy is the rotational passive movement of the lower leg about the knee from 90 to 180 degrees of rotation... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
03/13/2025
Locations: University of Nebraska - Omaha, Omaha, Nebraska
Conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Peripheral Artery Occlusive Disease, Peripheral Artery Disease
ENhancing Exercise with LIGHT to Improve Functioning in PAD
Recruiting
The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/10/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Aging, Walking, Difficulty
Far Red Light to Improve Functioning in PAD
Recruiting
The LIGHT PAD Trial is a Phase II multi-centered randomized clinical trial to collect preliminary data to test whether daily far red light treatment of the lower extremities in people with PAD improves six-minute walk distance, lower extremity perfusion, and ischemia-related damage in gastrocnemius muscle at four-month follow-up, compared to a sham control. Participants will complete 10 minutes of twice daily home treatment with either far red light or a sham light for four months.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/30/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Aging, Walking, Difficulty
1 - 3 of 3
